John (Jack) B. Henneman
John B. (“Jack”) Henneman, III has worked in the medical technology and biotechnology industries for 25 years. Jack has served as the Executive Vice President, Chief Financial Officer, and Secretary of NewLink Genetics Corporation, a NASDAQ listed immuno-oncology company, since October 2014. Prior to joining NewLink, Jack served for sixteen years at Integra LifeSciences, a publicly traded medical devices company. He joined Integra in 1998 as General Counsel and Chief Administrative Officer, was appointed Acting Chief Financial Officer in 2007 and assumed that role permanently in 2008. During his 16 years at Integra, in addition to his duties as Chief Financial Officer, he was responsible at various times for Integra’s law department, corporate development, regulatory affairs, quality systems, clinical affairs, human resources, information systems, was executive sponsor of Integra’s surgical instruments business, led or executed more than 40 acquisitions and alliances, and raised more than $1 billion in debt and equity financing. Jack currently serves on the Board of Directors of R1 RCM, Inc., a NASDAQ listed company that provides revenue cycle management services to hospitals and physician practices, SeaSpine Holdings Corporation, a NASDAQ listed company that is a spinal implant and orthobiologics company, and Alafair Biosciences, a privately-held biomaterials company. Finally, Jack serves on the advisory board of Transcode Therapeutics, Inc., a start-up biotechnology company focused on pharmaceutical inactivation of microRNA. Jack grew up in Iowa City, lives in Austin, Texas, and received his A.B. in Politics from Princeton University and a J.D. from the University of Michigan Law School.